Israel's FutuRx, US-based Atomwise enter into strategic partnership
The A2i Therapeutivs joint venture project will be funded by the Israeli Innovation Authority, FutuRx investors and addition resources and support provided by Atomwise.
An individual dose of the filled SARS-CoV-2 vaccine candidate made by biotech company IDT Biologika in Dessau-Rosslau, Germany. June 24, 2020(photo credit: HARTMUT BOESENER/IDT BIOLOGIKA/HANDOUT VIA REUTERS)ByJERUSALEM POST STAFFUpdated:
